Biologic Treatment of Severe Asthma / 대한내과학회지
Korean Journal of Medicine
;
: 172-180, 2018.
Article
in Korean
| WPRIM
| ID: wpr-713793
ABSTRACT
Beyond the existing scope of asthma treatment, a number of biologics have recently been developed based on the immunopathological mechanism of severe asthma. Severe asthma has a wide variety of phenotypes or endotypes, more than half of which are associated with eosinophils or type 2 inflammation. This paper introduces newly developed biologics and those that are under development for treatment of asthma. The most successful biologics developed to date are anti-IgE and anti-interleukin (IL)-5 antibodies, followed by anti-IL-4, anti-IL-13, anti-prostaglandin D2 type 2 receptor, and anti-thymic stromal lymphopoietin antibodies. However, further studies on drugs that target type 1 inflammation are required.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phenotype
/
Asthma
/
Status Asthmaticus
/
Biological Products
/
Biological Therapy
/
Eosinophils
/
Inflammation
/
Antibodies
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS